Home CONTACT Neoplasma 2014 Neoplasma Vol.61, No.4, p.461-467, 2014

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.61, No.4, p.461-467, 2014

Title: PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer
Author: Y. ZHANG, M. LIU, H. YANG, J. WANG, H. LIU, X. LI, J. LI, J. XU, X. LI

Abstract: This study proposed to investigate the relationship of PIK3CA somatic mutations, the most common
activating mutations in human breast cancer (BC), and the efficacy of neoadjuvant chemotherapy
(NCT).Using a novel liquidchip technology, PIK3CA DNA somat ic mutations and HER2, PTEN,
EGFR mRNA expression profiles were analyzed in formalin fixed paraffin embedded samples of 93.

Keywords: PIK3CA somatic mutation, NCT, breast cancer, epirubicin, docetaxel
Published online: 25-Mar-2014
Year: 2014, Volume: 61, Issue: 4 Page From: 461, Page To: 467

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.